Figure 1.
Figure 1. Low titers of AAV2 neutralizing antibodies abrogate AAV2-hFIX transduction. SCID mice received intravenous injections of 0.89 and 8.9 mg human IVIG (ZLB, Bioplasma), which resulted in AAV2 neutralizing antibody titer ranges from 4.3 to 12.5 and from 33.3 to 133.3, respectively, as indicated for individual mice. Twenty-four hours later, 5 × 1011 vg of AAV2-hFIX was administered intravenously. Plasma human FIX levels were measured in individual mice 4 weeks after AAV treatment. Error bars indicate SD of replicate samples in ELISA assay.

Low titers of AAV2 neutralizing antibodies abrogate AAV2-hFIX transduction. SCID mice received intravenous injections of 0.89 and 8.9 mg human IVIG (ZLB, Bioplasma), which resulted in AAV2 neutralizing antibody titer ranges from 4.3 to 12.5 and from 33.3 to 133.3, respectively, as indicated for individual mice. Twenty-four hours later, 5 × 1011 vg of AAV2-hFIX was administered intravenously. Plasma human FIX levels were measured in individual mice 4 weeks after AAV treatment. Error bars indicate SD of replicate samples in ELISA assay.

Close Modal

or Create an Account

Close Modal
Close Modal